Binaytara shared a post on LinkedIn:
“If you put together all the lives, all the cancers cured by immunotherapy, targeted therapy, novel bispecifics, all of them together, they cannot really reach the number of lives saved by chemotherapy.”
A line from Dr. Paolo Tarantino’s keynote at our Detroit 2026 Hematology and Oncology Practice Symposium that’s worth sitting with:
Despite remarkable progress in immunotherapy, targeted therapy, and bispecifics, chemotherapy still accounts for more cancer lives saved than any other class of treatment in oncology’s history.
It’s a useful reminder when we talk about ADCs. The reason antibody-drug conjugates matter isn’t that they replace chemotherapy – it’s that they deliver it more precisely, extend its effective half-life in circulation, and help overcome the resistance that develops across sequential lines.
The innovation isn’t moving past chemo. It’s making chemo work better, for longer, with a more favorable therapeutic window.
How are you framing this with your patients who hear ‘ADC’ and assume it means ‘not chemotherapy’?
Read more about Dr Tarantino’s keynote.”
Other articles featuring Paolo Tarantino on OncoDaily.